Introduction: Chylothorax is a disease that will cause malnutrition and compromise immunity in infant and children. Current management of chylothorax include medication and surgical intervention. Octreotide is a somatostatin analogue that has been used to treat chylothorax in children. Case: A male newborn was born at gestational age 38 + 1 weeks, birth weight 3,160 gm, and Apgar score 5 turned to 7 at 1 and 5 minutes after birth. Patient was admitted to neonate intensive care unit because of respiratory failure. Chylothorax was highly suspected based on clinical presentation. Octreotide intravenous infusion was used for 11 days and chylothorax was successfully managed. Patient was discharged without chylothorax recurrence. Discussion: Octreotide had shown efficacy for treating congenital chylothorax in previous case report and systematic review. The optimal dose and treatment duration was not determined and several cases had recurrence after initial success. Octreotied had been reported to cause metabolic dysfunction, cholelithiasis and biliary stone. Pediatrician s and pharmacists should be aware of potential harm of octreotide when treating congential chylothorax.